Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2022 | Highlights of ISLB 2022

Massimo Cristofanilli • 31 Oct 2022
ISLB 2022
General

Massimo Cristofanilli, MD, FACP, Weill Cornell Medicine, New York, NY, discusses the highlights of ISLB 2022, including discussions on clinical applications of liquid biopsy, improvements to future study designs, and the benefit of collaboration among a range of healthcare professionals. This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant for: Menarini, Lilly, AZ, Ellipses, Celcuity, Olaris, Sermonix
Grant/Research support from: Pfizer, Lilly, AZ
Honoraria from: Pfizer, Lilly, Foundation Medicine, Guardant

More from Massimo Cristofanilli

Developments in liquid biopsy for breast cancer over 10 years
3:40
Developments in liquid biopsy for breast cancer over 10 years
Massimo Cristofanilli • 31 Oct 2022
The role of circulating tumor cell clusters in advanced disease
3:07
The role of circulating tumor cell clusters in advanced disease
Massimo Cristofanilli • 31 Oct 2022
PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer
5:04
PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer
Massimo Cristofanilli • 20 Oct 2018

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals